- Home
- PPBT vs SSY Comparison
PPBT vs SSY Comparison
Compare PPBT & SSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- SSY
- Stock Information
- Founded
- PPBT 2010
- SSY 1959
- Country
- PPBT Israel
- SSY United States
- Employees
- PPBT N/A
- SSY N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- SSY Hospital/Nursing Management
- Sector
- PPBT Health Care
- SSY Health Care
- Exchange
- PPBT Nasdaq
- SSY Nasdaq
- Market Cap
- PPBT 6.2M
- SSY 6.8M
- IPO Year
- PPBT N/A
- SSY N/A
- Fundamental
- Price
- PPBT $2.33
- SSY $1.36
- Analyst Decision
- PPBT Strong Buy
- SSY
- Analyst Count
- PPBT 1
- SSY 0
- Target Price
- PPBT $33.00
- SSY N/A
- AVG Volume (30 Days)
- PPBT 251.5K
- SSY 200.2K
- Earning Date
- PPBT 08-15-2025
- SSY 05-13-2025
- Dividend Yield
- PPBT N/A
- SSY 7.35%
- EPS Growth
- PPBT N/A
- SSY N/A
- EPS
- PPBT N/A
- SSY 0.25
- Revenue
- PPBT N/A
- SSY $31,094,000.00
- Revenue This Year
- PPBT N/A
- SSY N/A
- Revenue Next Year
- PPBT N/A
- SSY N/A
- P/E Ratio
- PPBT N/A
- SSY $5.55
- Revenue Growth
- PPBT N/A
- SSY N/A
- 52 Week Low
- PPBT $2.00
- SSY $0.62
- 52 Week High
- PPBT $13.95
- SSY $1.91
- Technical
- Relative Strength Index (RSI)
- PPBT 40.95
- SSY 79.08
- Support Level
- PPBT $2.35
- SSY $1.12
- Resistance Level
- PPBT $2.90
- SSY $1.36
- Average True Range (ATR)
- PPBT 0.17
- SSY 0.12
- MACD
- PPBT 0.00
- SSY 0.03
- Stochastic Oscillator
- PPBT 13.29
- SSY 93.18
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.